Home  >  Investors  >  Debt Information  >  Debt Information

Debt Information

Teva's senior notes and debentures and convertible debentures are issued by various special-purpose finance subsidiaries. All such debt is guaranteed by Teva Pharmaceutical Industries Ltd.

Quarterly Debt Factsheet

Senior Notes and Debentures

Issued
Currency
Annual Interest
(%)
Principal Amount Issued
(U.S. $ in MM)
Current Outstanding
Due
Prospectuses
January 2006 USD 6.150 1,000 782 January 2036
November 2011 USD 3.650 1,750 1,209 November 2021
April 2012 CHF 1.500 459 458 October 2018
December 2012 USD 2.250 700 700 March 2020
December 2012 USD 2.950 1,300 862 December 2022
March 2015 Euro 1.250 1,446 1,501 March 2023
March 2015 Euro 1.875 779 810 March 2027
July 2016 USD 1.700 2,000 1,700 July 2019
July 2016 USD 2.200 3,000 2,997 July 2021
July 2016 USD 2.800 3,000 2,993 July 2023
July 2016 USD 3.150 3,500 3,493 October 2026
July 2016 USD 4.100 2,000 1,984 October 2046
July 2016 CHF 0.125 306 0 July 2018
July 2016 CHF 0.500 357 357 July 2022
July 2016 CHF 1.000 357 357 July 2025
July 2016 Euro 0.375 1,947 1,924 July 2020
July 2016 Euro 1.125 1,669 1,731 October 2024
July 2016 Euro 1.625 834 863 October 2028
March 2018 USD 6.000 1,250 1,250 April 2024
March 2018 USD 6.750 1,250 1,250 March 2028
March 2018 Euro 3.250 867 812 April 2022
March 2018 Euro 4.500 1,115 1,045 March 2025

Convertible Senior Debentures

Issued Annual interest rate Initial Principal amount Principal amount at 3/31/2017 Year due Conversion price August 2018 No of Teva shares issuable upon full conversion at 3/31/2017 Earliest date of redemption at issuer's option / repurchase at holder's option
  (%) (U.S. $ in MM)   (U.S. $) (in MM)  
January 2006(1) 0.25 $575 $514 2026 $39.7841 See footnote 1 Issuer - on demand
Holders - on 2/1/2021

To view the prospectus supplement relating to the January 2006 debentures - click here
For conversion and other notices - click here

(1) These convertible senior debentures due 2026 include a "net share settlement" feature according to which the principal of the debentures will be paid in cash and in the case of conversion, only the residual conversion value above the principal will be paid in Teva shares.

Term Loans and Other Facilities

Source Year
of
Facility
Currency Annual
Interest Rate (%)
Principal Amount
Issued
Due Additional Information
      (%) (U.S. $ in MM)
 

Revolving Credit Facility*

2015 USD USD Libor +1.875 - N/A $3.0 b facility available for 5 years

*The following amendments document apply to the term loans and revolving credit facility noted above

Covenant Amendments – February 2018

Covenant Amendments – September 2017